Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
GlaxoSmithKline Pharmaceuticals is the Indian listed arm of GSK plc, selling prescription medicines led by anti-infectives (Augmentin, Ceftum), dermatology, and respiratory products, plus paracetamol brand Calpol. Its vaccines portfolio spans paediatric vaccines and the Shingrix shingles vaccine in the private market. Revenue is driven by a concentrated set of large power brands in the domestic formulations market.
A top multinational pharma company in the Indian prescription market.
Glaxosmithkline Pharmaceuticals Ltd. is a constituent of NIFTY 500, NIFTY MIDCAP 150. See where it sits on the market heatmap →
Consolidated annual figures taken from Glaxosmithkline Pharmaceuticals Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 54.52 | 54.52 | 34.83 |
| Book value / share (₹) | 134.86 | 115.18 | 104.93 |
| Return on equity | 45.3% | 47.5% | 33.2% |
| Return on capital employed | 48.8% | 50.4% | 41.3% |
| Operating margin | 32.5% | 29.6% | 24.3% |
| Net margin | 27.1% | 24.7% | 17.1% |
| EBITDA | ₹1,309 Cr | ₹1,177 Cr | ₹909 Cr |
| Free cash flow | ₹848 Cr | ₹1,267 Cr | ₹551 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Debt to equity | 0.00 | 0.00 | 0.00 |
| Interest coverage | 455.2 | 847.8 | 466.1 |
| Current ratio | 2.13 | 1.89 | 1.98 |
| Shares outstanding | 16,94,10,000 | 16,94,10,000 | 16,94,10,000 |
Open the full income statement, balance sheet and cash flow for GLAXO →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.